Sarcomas

01-C-0091: A Phase I Trial and Pharmacokinetic Study of Tariquidar, a P-Glycoprotein Inhibitor, in Combination with Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients with Refractory Solid Tumors Including Brain Tumors

Principal Investigator: Frank Balis

99-C-0125 A Pilot Study of The Outcome of Therapy Based on Histologic Response. A Collaborative Effort of the POB/NCI, Texas Children's Hospital and University of Oklahoma

Principal Investigator: Lee Helman

00-C-0092: A Randomized Trial of Filgrastim-SD/01 vs Filgrastim in Newly Diagnosed Children and Young Adults with Sarcoma Treated with Dose-Intensive Chemotherapy

Principal Investigator: Frank Balis

02-C-0259: Pilot Study of Allogeneic Blood Stem Cell Transplantation in Patients with High-Risk and Recurrent Pediatric Sarcomas

Principal Investigator: Terry Fry

04-C-0080:Phase II Trial of Pirfenidone in children, Adolescents, and Young Adults withNeurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Principal Investigator: Brigitte Widemann

04-C-0001: Phase II Study of Sequential Gemcitabine Followed by Docetaxel for RecurrentEwing’s Sarcoma, Osteosarcoma, or Unresectable or Locally RecurrentChondrosarcoma

Principal Investigator: Elizabeth Fox

03-C-0216: A Groupwide Biology and Banking Study for Ewing Sarcoma: Children's Oncology Group

Principal Investigator: Lee Helman

05-C-0235: A phase I study of valproic acid in children with recurrent/progressive solid tumors including CNS tumors

Principal Investigator: Elizabeth Fox

05-C-0239: A phase I trial and pharmacokinetic study of talabostat in combination with temozolomide or carboplatin in pediatric patients with relapsed or refractory solid tumors including brain tumors

Principal Investigator: Frank Balis

06-C-0052: A Phase I Study of CC-5013 (Lenalidomide, NSC#703813, IND#70116) In Relapse / Refractory Solid Tumors or Myelodysplastic Syndrome

Principal Investigator: Elizabeth Fox

02-C-0031: A Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428), an Epothilone B Analog, in Pediatric Patients with Refractory Solid Tumors

Principal Investigator: Brigitte Widemann

06-C-0146: Phase II trial of Ixabepilone (BMS-247550), an epothilone B analog, in children and young adults with refractory sarcomas

Principal Investigator: Brigitte Widemann

06-C-0152: Phase I Trial of AZD2171, an orally bioavailable antiangiogenic agent, in pediatric patients with refractory or recurrent solid tumors or acute myelogenous leukemia

Principal Investigator: Elizabeth Fox

Last Updated: :July 25, 2006

NCI Home Page|| NIH Home Page

© 2002-2003, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute